Ultragenyx Secures UK Approval for Triheptanoin's Oral Liquid Formulation to Treat LC-FAOD Rare Inherited Disorders

11:31 AM EDT, 10/30/2026 (MT Newswires) -- Ultragenyx (RARE) has secured the UK Medicines and Healthcare products Regulatory Agency's approval for an oral liquid formulation of triheptanoin, or Dojolvi, to treat adult and paediatric patients with long-chain fatty acid oxidation disorders or LC-FAOD, the regulator said Friday. The product has a conditional marketing authorization, as further proof of its efficacy and safety from an ongoing paediatric study is required for a full marketing authorization, MHRA said. Triheptanoin is a liquid that is taken daily by mouth, as part of a carefully controlled diet, according to the statement. Price: 16.14, Change: -0.64, Percent Change: -3.81